Aclarion shares rise 12.43% intraday after Nociscan featured in IJSS Special Pain Issue with successful case study.

Aclarion Inc. (NASDAQ: ACON) surged 12.43% intraday after its Nociscan solution was featured in the Special Pain Issue of the International Journal of Spine Surgery (IJSS). The publication highlighted a case study demonstrating Nociscan’s ability to noninvasively identify painful lumbar discs, enabling a surgeon to target treatment to a single disc rather than two, resulting in the patient’s full recovery. The feature in a peer-reviewed journal underscores Nociscan’s clinical validation and potential to improve spine care, enhancing the company’s credibility. Additionally, Aclarion reported an 89% year-over-year increase in Nociscan scan volumes for Q3 2025, signaling growing adoption. These developments collectively drove investor optimism about the company’s market position and growth prospects in the chronic low back pain diagnostics sector.